A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
Status:
RECRUITING
Trial end date:
2029-09-30
Target enrollment:
Participant gender:
Summary
Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D). However, intensive control to near-normal glycated hemoglobin (HbA1c) yielded complex results in previous landmark trials. Potential risks of intensive glycemic control, such as hypoglycemia and weight gain, may partly contributed to the possible harms associated with this approach. Recent advances in diabetes management with development of newer antidiabetic drugs which minimize possible harms of intensive glycemic control as well as reduce cardiorenal risks enabled safer glycemic reduction. Thus, this randomized trial aims to evaluate the effects of near normalization of HbA1c with novel approaches on microvascular complications and cardiovascular outcomes in people with T2D.
Phase:
NA
Details
Lead Sponsor:
Kyu Chang Won
Collaborators:
Boryung Pharmaceutical Co., Ltd Celltrion Chong Kun Dang Pharmaceutical Corp. Daewoong Pharmaceutical Co. LTD. Dong-A ST Co., Ltd. Handok Inc. HK inno.N Corporation Kakao Healthcare Corp.